Alcobra’s Fragile X Syndrome Drug Fails Phase 2 Trial

Clinical Trials Advisor
A A
Israeli drugmaker Alcobra’s only drug, MDX, failed a Phase 2 trial to treat Fragile X Syndrome, which can cause autism and ADHD.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00